clinical trial · NCT05848128
Efficacy and Safety Evaluation of Tavilermide Ophthalmic Solution for the Treatment of Dry Eye
Mimetogen Pharmaceuticals USA, Inc.·phase3·completed·n = 642
Dry Eye SyndromesDry Eye DiseaseKerato Conjunctivitis Sicca5% Tavilermide ophthalmic solutionVehicle ophthalmic solution
brief summary
The purpose of the study is to compare the efficacy and safety of 5% tavilermide ophthalmic solution to placebo for the treatment of the signs and symptoms of dry eye disease.
started
Jun 28, 2023
primary completion
May 11, 2024
completion
May 11, 2024
last updated
Jun 10, 2024
official title
A Phase 3, Multicenter, Randomized, Double-Masked, Vehicle-Controlled Clinical Study to Assess the Efficacy and Safety of 5% Tavilermide Ophthalmic Solution for the Treatment of Dry Eye
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol